BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer

Mutational activation of KRAS is a common oncogenic event in lung cancer, yet effective therapies are still lacking. Here, we identify B cell lymphoma 6 (BCL6) as a lynchpin in KRAS-driven lung cancer. BCL6 expression was increased upon KRAS activation in lung tumor tissue in mice and was positively...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Kun, Liu, Yanan, Ding, Yi, Zhang, Zhengwei, Feng, Juanjuan, Hu, Jiaxin, Chen, Jiwei, Lian, Zhengke, Chen, Yiliang, Hu, Kewen, Chen, Zhi, Cai, Zhenyu, Liu, Mingyao, Pang, Xiufeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663163/
https://www.ncbi.nlm.nih.gov/pubmed/36377663
http://dx.doi.org/10.1172/JCI161308

Ejemplares similares

Ejemplares similares